01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
18:13 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Replimune prices $100.5M IPO in middle of range

Replimune Group Inc. (NASDAQ:REPL) raised $100.5 million late July 19 through the sale of 6.7 million shares at $15 in an IPO underwritten by J.P. Morgan, Leerink and BMO Capital Markets. The price, which was...
02:48 , Jul 20, 2018 |  BC Extra  |  Financial News

Replimune ticks up after pricing $100.5M IPO

Replimune Group Inc. (NASDAQ:REPL) gained $0.16 to $15.16 on Friday after it raised $100.5 million through the sale of 6.7 million shares at $15 in an IPO. Underwriters are J.P. Morgan, Leerink and BMO Capital...
21:39 , Jun 23, 2018 |  BC Extra  |  Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
11:06 , Sep 8, 2017 |  BioCentury  |  Product Development

Maximizing neoantigens

In conjunction with raising $55 million in a series B round on Friday, Replimune Group Inc. unveiled details of its Immulytic oncolytic virus platform, including next-generation constructs that underpin the company’s strategy for creating multimodal...
11:05 , Sep 8, 2017 |  BC Extra  |  Financial News

Replimune raises $55M in a series B round

Replimune Group Inc. (Woburn, Mass.) raised $55 million in a series B round led by Foresite Capital. Fellow new investors Bain Capital Life Sciences, Redmile Group, Cormorant Asset Management and affiliates with Leerink joined existing...
00:53 , Jan 14, 2017 |  BioCentury  |  Finance

Omega’s trans-Atlantic bridge

As Omega Funds has moved its center of gravity from Switzerland to the U.S., it has wanted to keep its access to European deals that could turn into big successes in the U.S. like Micromet...
07:00 , Aug 15, 2016 |  BioCentury  |  Product Development

No antigen left behind

Amgen Inc. partnered with Advaxis Inc. to develop a personalized neoantigen therapy platform with potential to invoke a broad immune response by both stimulating the immune system on multiple fronts and delivering the full repertoire...
07:00 , Aug 2, 2016 |  BC Extra  |  Company News

Amgen licenses Advaxis' neoantigen therapy

Advaxis Inc. (NASDAQ:ADXS) jumped $2.61 (31%) to $11.08 on Tuesday after it granted Amgen Inc. (NASDAQ:AMGN) exclusive, worldwide rights to develop and commercialize ADXS-NEO, a patient-specific cancer immunotherapy that is expected to start clinical testing...
08:00 , Feb 29, 2016 |  BioCentury  |  Product Development

The BioVex effect

The BioVex effect In the last five years, oncolytic virus companies raised $360.2 million via equity offerings, topping the $321.5 million raised in 2000-10. The catalyst of renewed attention to the space was the early...